Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totaling 402,126 shares, a growth of 22,315.1% from the June 30th total of 1,794 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 75,614 shares, the days-to-cover ratio is presently 5.3 days.
Raia Drogasil Stock Down 2.3%
OTCMKTS RADLY opened at $3.53 on Friday. Raia Drogasil has a 1-year low of $2.33 and a 1-year high of $5.34. The firm’s fifty day simple moving average is $3.56 and its 200-day simple moving average is $4.27.
Analysts Set New Price Targets
Separately, Zacks Research raised shares of Raia Drogasil to a “hold” rating in a research report on Thursday, April 9th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold”.
Raia Drogasil Company Profile
Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.
The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.
Featured Stories
- Five stocks we like better than Raia Drogasil
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
